Abstract 1341P
Background
The aim of PISCES study is to assess the molecular testing, treatment patterns and clinical outcomes among Chinese patients progressed on first-line (1L) EGFR-TKI monotherapy in real-world setting.
Methods
This prospective study enrolled EGFR mutant, locally advanced or metastatic NSCLC patients progressed on 1L EGFR-TKI monotherapy from May 2020 to May 2021 in 16 Chinese hospitals. The treatment patterns and clinical outcomes were recorded.
Results
292 patients received 1L EGFR-TKI monotherapy were enrolled. 93.8% (274/292) of patients received first/second generation (1/2G) EGFR-TKI and 6.2% (18/292) received third generation (3G) EGFR-TKI. 74.8% (205/274) of patients who progressed on 1L 1/2G EGFR-TKI underwent genetic testing, and 47.8% (98/205) of them were T790M positive (T790M+). 91.8% (90/98) of T790M+ patients received 3G EGFR-TKI as 2L therapy. Among the 107 patients with T790M negative (T790M-), 47.8% (51/107) received 3G EGFR-TKI, 25.2% (27/107) received chemotherapy and 8.4% (9/107) received prior 1/2G EGFR-TKI plus local therapy as 2L therapy. Among 18 patients progressed on 1L 3G EGFR-TKI, half (9/18) of them received chemotherapy, 27.8% (5/18) switched to another 3G EGFR-TKI. The overall median PFS (mPFS) of patients who had received 2L treatment was 9.1 months (95%CI, 7.6-11.2). The mPFS of patients receiving 2L 3G EGFR-TKI, prior 1/2G EGFR-TKI plus local therapy, and chemotherapy was 10.5 months (95%CI, 8.7-13.7), 10.2 months (95%CI, 5.3-19.2) and 5.5 months (95%CI, 3.3-8.6), respectively. Among those receiving 2L 3G EGFR-TKI treatment, T790M+ patients achieved significantly longer mPFS compared to T790M- patients (13.7 vs 7.6 months, P=0.012). For patients with T790M-, the mPFS was comparable (7.6 vs 5.5 months, P=0.07) when received 3G EGFR-TKI and chemotherapy as 2L therapy.
Conclusions
Most patients progressed on 1L EGFR-TKI monotherapy underwent genetic testing in Chinese real-world setting. The vast majority of T790M+ patients received 3G EGFR-TKIs treatment. Although almost half of T790M- patients received 3G EGFR-TKI as 2L therapy, these patients achieved suboptimal clinical outcome.
Clinical trial identification
NCT04207775.
Editorial acknowledgement
Legal entity responsible for the study
AstraZeneca.
Funding
AstraZeneca.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1037P - Phase I dose-escalation trial with tumor-targeted interleukin-12 (IL12-L19L19) in patients with solid tumors
Presenter: Nicolas Mach
Session: Poster session 19
1039P - First-in-human phase I study of givastomig, a novel Claudin 18.2/4-1BB bispecific antibody in advanced solid tumors
Presenter: Geoffrey Ku
Session: Poster session 19
1040P - Phase I study of IL-8 inhibitor AMY109 plus atezolizumab (atezo) in patients (pts) with advanced solid tumours
Presenter: Yasutoshi Kuboki
Session: Poster session 19
1041P - Phase I open-label, dose escalation and expansion study of YH003, an anti-CD40 agonist monoclonal antibody in combination with toripalimab in patients (pts) with advanced solid tumours
Presenter: Ben Markman
Session: Poster session 19
1042P - INSIGHT 003 evaluating feasibility of eftilagimod alpha (soluble LAG-3) combined with first-line chemo-immunotherapy in metastatic non-small cell lung cancer (NSCLC) adenocarcinomas
Presenter: Akin Atmaca
Session: Poster session 19
1043P - First-in-human study of TU2218, TGFβRI and VEGFR2 dual inhibitor in patients with advanced solid tumors
Presenter: Do-Youn Oh
Session: Poster session 19
1044P - A phase Ia first-in-human study of JS007, a novel anti-CTLA-4 monoclonal antibody, in patients with advanced solid tumors
Presenter: Jun Zhang
Session: Poster session 19
1045P - Safety and preliminary clinical activity of JNJ-78306358 (JNJ-358), an HLA-G and CD3 bispecific antibody, for the treatment of advanced stage solid tumor
Presenter: Ravit Geva
Session: Poster session 19
1046P - Phase I/II open-label study on an anti-GPC3 T cell engager, SAR444200, in patients with advanced solid tumors: Preliminary dose escalation results
Presenter: Jung Yong Hong
Session: Poster session 19